IONS - IONIS PHARMACEUTICALS INC
IEX Last Trade
36.5
-0.010 -0.027%
Share volume: 22,934
Last Updated: Thu 26 Dec 2024 08:30:12 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$36.51
-0.01
-0.03%
Fundamental analysis
13%
Profitability
8%
Dept financing
24%
Liquidity
75%
Performance
0%
Performance
5 Days
1.25%
1 Month
3.28%
3 Months
-11.12%
6 Months
-23.42%
1 Year
-28.79%
2 Year
-1.70%
Key data
Stock price
$36.50
DAY RANGE
$35.93 - $36.61
52 WEEK RANGE
$34.42 - $54.44
52 WEEK CHANGE
-$27.66
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Brett P. Monia
Region: US
Website: ionispharma.com
Employees: 800
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: ionispharma.com
Employees: 800
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy.
Recent news